Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0025 plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced or metastatic non-squamous NSCLC
CTR20260282Phase 3Active
- Sponsor
- Huabo Biopharm
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sotiburafusp alfa in Non-small cell lung cancer (NS-NSCLC), sponsored by Huabo Biopharm. Started Feb 2026; status: active.
02
Drugs
sotiburafusp alfa
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20260282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260282.